These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 33693944

  • 1. Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.
    Chatzimavridou-Grigoriadou V, Al-Othman S, Brabant G, Kyriacou A, King J, Blackhall F, Trainer PJ, Higham CE.
    J Clin Endocrinol Metab; 2021 Oct 21; 106(11):e4766-e4775. PubMed ID: 33693944
    [Abstract] [Full Text] [Related]

  • 2. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM.
    Clin Endocrinol (Oxf); 2016 Apr 21; 84(4):620-6. PubMed ID: 26385871
    [Abstract] [Full Text] [Related]

  • 3. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW, Yi JH, Kang KP, Kim HY, Kim SW, Choi HY, Ha SK, Kim GH, Kim YW, Jeong KH, Shin SK, Kim HJ.
    J Korean Med Sci; 2018 Apr 09; 33(15):e112. PubMed ID: 29629516
    [Abstract] [Full Text] [Related]

  • 4. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 09; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 5. Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.
    Indirli R, Ferreira de Carvalho J, Cremaschi A, Mantovani B, Sala E, Serban AL, Locatelli M, Bertani G, Carosi G, Fiore G, Tariciotti L, Arosio M, Mantovani G, Ferrante E.
    Front Endocrinol (Lausanne); 2021 Jun 09; 12():689887. PubMed ID: 34108941
    [Abstract] [Full Text] [Related]

  • 6. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A, McCormick L, Rahman M.
    Adv Ther; 2021 Dec 09; 38(12):5721-5736. PubMed ID: 34693505
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.
    Bilgetekin I, Erturk I, Basal FB, Karacin C, Karadurmus N, Oksuzoglu B, Demirci U.
    Int Urol Nephrol; 2021 Feb 09; 53(2):301-307. PubMed ID: 32869173
    [Abstract] [Full Text] [Related]

  • 8. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA, Cranston IC.
    BMC Endocr Disord; 2017 Nov 06; 17(1):69. PubMed ID: 29110656
    [Abstract] [Full Text] [Related]

  • 9. Urea in cancer patients with chronic SIAD-induced hyponatremia: Old drug, new evidence.
    Nervo A, D'Angelo V, Rosso D, Castellana E, Cattel F, Arvat E, Grossi E.
    Clin Endocrinol (Oxf); 2019 Jun 06; 90(6):842-848. PubMed ID: 30868608
    [Abstract] [Full Text] [Related]

  • 10. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 06; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 06; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 12. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP, DeVita MV, Michelis MF.
    Int Urol Nephrol; 2012 Jun 06; 44(3):865-71. PubMed ID: 21607553
    [Abstract] [Full Text] [Related]

  • 13. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
    Rajendran R, Grossman AB, Kar P.
    Endocr J; 2012 Jun 06; 59(10):903-9. PubMed ID: 22785335
    [Abstract] [Full Text] [Related]

  • 14. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S, Aydın Kaderli A, Yıldız A, Gül BC, Özdemir B, Baran İ, Güllülü S, Aydınlar A, Çavuşoğlu Y.
    Turk Kardiyol Dern Ars; 2017 Jul 06; 45(5):415-425. PubMed ID: 28694395
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Oral Tolvaptan Therapy in Hospitalized Cirrhotic Patients with Hyponatremia.
    Garg R, Kaur K, Aggarwal S, Singh N.
    J Assoc Physicians India; 2018 Dec 06; 66(12):49-52. PubMed ID: 31315326
    [Abstract] [Full Text] [Related]

  • 16. Acute hyponatremia after aneurysmal subarachnoid hemorrhage: Frequency, treatment, and outcome.
    Kieninger M, Kerscher C, Bründl E, Bele S, Proescholdt M, Zeman F, Graf B, Schmidt NO, Schebesch KM.
    J Clin Neurosci; 2021 Jun 06; 88():237-242. PubMed ID: 33992191
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.
    Kai K, Tominaga N, Koitabashi K, Ichikawa D, Shibagaki Y.
    CEN Case Rep; 2019 May 06; 8(2):112-118. PubMed ID: 30637666
    [Abstract] [Full Text] [Related]

  • 18. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.
    Salahudeen AK, Ali N, George M, Lahoti A, Palla S.
    Cancer; 2014 Mar 01; 120(5):744-51. PubMed ID: 24895288
    [Abstract] [Full Text] [Related]

  • 19. Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma.
    Gürbüz F, Taştan M, Turan İ, Yüksel B.
    J Clin Res Pediatr Endocrinol; 2019 May 28; 11(2):202-206. PubMed ID: 30257818
    [Abstract] [Full Text] [Related]

  • 20. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.